ClinicalTrials.Veeva

Menu

Improving Implementation of Lung Cancer Screening in Diverse Populations II

University of Washington logo

University of Washington

Status

Completed

Conditions

Early Detection of Cancer
Lung Cancer

Treatments

Other: CAQ

Study type

Interventional

Funder types

Other

Identifiers

NCT05265897
SITE00000215

Details and patient eligibility

About

This project assesses the feasibility, appropriateness, and acceptability of a "Commonly Asked Questions after Lung Cancer Screening" (CAQ) informational document that the investigators created, resulting from patient and provider discussion in focus groups and interviews. If effective, the CAQ may be a new tool to help improve patient understanding of LCS results and adherence to follow-up recommendations.

Full description

Barriers to optimal implementation of lung cancer screening (LCS) include low levels of patient knowledge. Patient understanding of LCS results may alleviate distress and improve understanding of recommendations. The investigators developed a "Commonly Asked Questions after LCS" (CAQ) information sheet based on gaps in knowledge identified by patient focus groups and provider interviews. The study objective was to assess CAQ appropriateness and acceptability, and preliminary impact on patient understanding and distress after receiving LCS results.

The investigators conducted a pilot alternating intervention controlled trial of the CAQ. All patients in the University of Washington/Seattle Cancer Care Alliance LCS program who underwent baseline or annual LCS were received a mailing within one week of their scan, either: 1) usual care: a brief form letter with screening results; or 2) usual care plus the CAQ (intervention). The mailing assignment was alternated weekly. Mailed follow-up surveys assessed appropriateness and acceptability of CAQ as well as LCS knowledge in the intervention group.

Primary outcomes include: 1) Ratings of "I understand the results of my most recent LCS CT scan" on a Likert Scale; 2) Correct self-report of next step based on Lung-RADS standardized follow-up; 3) symptoms of distress (measured by IES); as well as 4) measures of acceptability and appropriateness. Secondary outcomes include responses to 6 questions regarding lung cancer screening knowledge.

Enrollment

230 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Has undergone LCS or is referred for LCS
  • Able to give informed consent

Exclusion criteria

  • Cognitive or language limitations (i.e., expressive language limitations, non-English speaking
  • Known malignancy other than non-melanoma skin cancer

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

230 participants in 2 patient groups

Usual Care
No Intervention group
Description:
Brief form letter with lung cancer screening results
CAQ
Experimental group
Description:
Usual care, plus "Commonly Asked Questions after Lung Cancer Screening" informational document (CAQ)
Treatment:
Other: CAQ

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems